NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
Clinical trial NCT04659629 · COMPLETED
Trial details
- NCT number
- NCT04659629
- Sponsor
- Neurogene Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-26
- Primary completion
- 2022-12-15
- Enrollment
- 59
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.